Cromos Pharma has announced the appointment of Stephanie Finnegan as its chief operating officer. Ms. Finnegan will join the company’s US office and will oversee its European and US operations.

“We are very excited to see Ms. Finnegan joining our team,” said Dr. Vlad Bogin, Cromos Pharma’s chief executive officer. “She brings decades of clinical research and business development experience and her addition marks a quantitative change in the company’s development.”

“Joining Cromos Pharma was an easy decision for me,” Ms. Finnegan said.  “After meeting with Dr. Bogin and the leadership team at Cromos, I knew that this was the right fit.  The team is talented, eager, and dedicated to unimpeachable quality and client service. There is limitless potential here and I am honored to become a member of the Cromos family.”

Ms. Finnegan has nearly three decades of experience in the biopharmaceutical industry. Prior to joining Cromos, she was the president of a CRO that operated predominantly in Eastern Europe, and helped to lead that company into the global market and establish a dominant position in biologics and biosimilars.